ReviewThe Journal of antimicrobial chemotherapy2008
Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence.
Review in The Journal of antimicrobial chemotherapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 3 syntheses or guidelines pooled it, 187 citations in OpenAlex.
- Resistance of Gram-Negative Bacteria to Eravacycline: A Systematic Review of Data from In Vitro Studies.Pathogens (Basel, Switzerland) · 2025Pooled it
- Global Epidemiology and Antimicrobial Resistance of Metallo-β-Lactamase (MBL)-Producing Acinetobacter Clinical Isolates: A Systematic Review.Pathogens (Basel, Switzerland) · 2025Pooled it
- Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies.The Journal of antimicrobial chemotherapy · 2008Pooled it
- Treatment Options for Metallo-Beta-Lactamase-ProducingInternational journal of molecular sciences · 2026Review
- Clinical Relevance of Antimicrobial Susceptibility Testing Methods in Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Carbapenem-ResistantMicroorganisms · 2025Review
- Reviving Furosemide as a Metallo-β-Lactamase Inhibitor against MDRJournal of microbiology and biotechnology · 2025Article
- Review
- Clinical and microbiological analysis of risk factors for breakthrough bloodstream infection during Tigecycline Therapy.Scientific reports · 2025Article
- Unveiling the Secrets ofInternational journal of molecular sciences · 2024Review
- Case Report: Management of recurrent UTI with tigecycline in a kidney transplant recipient.Frontiers in transplantation · 2024Article
- Six-year analysis of key monitoring for bacterial strain distribution and antibiotic sensitivity in a hospital.World journal of clinical cases · 2023Article
- Fecal Carriage ofAntibiotics (Basel, Switzerland) · 2022Article
- Clinical Outcomes and Safety of Meropenem-Colistin versus Meropenem-Tigecycline in Patients with Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2021Article
- Successful Treatment With Intrathecal and Intravenous Polymyxin B-Based Combination Against MDRFrontiers in pediatrics · 2021Article
- Hypofibrinogenemia induced by high-dose tigecycline-case report and review of literature.Medicine · 2020Review
- Epidemiological and phylogenetic analysis reveals Flavobacteriaceae as potential ancestral source of tigecycline resistance gene tet(X).Nature communications · 2020Article
- Outcomes and prognostic factors of tigecycline treatment for hospital-acquired pneumonia involving multidrug-resistantThe Journal of international medical research · 2020Article
- Insights intoAntibiotics (Basel, Switzerland) · 2020Review
- Calculated parenteral initial treatment of bacterial infections: Microbiology.GMS infectious diseases · 2020Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
objectivesNew antibacterial agents are required for the treatment of infections caused by multidrug-resistant (MDR) Acinetobacter spp. Whether tigecycline constitutes an effective treatment option or not, is not well established. We sought to evaluate the available evidence regarding the microbiological activity and clinical effectiveness of tigecycline for MDR (including the subset of carbapenem-resistant) Acinetobacter spp.
methodsWe searched PubMed for relevant articles and extracted/evaluated the available evidence.
resultsWe identified 22 microbiological studies reporting data for 2384 Acinetobacter spp. (1906 Acinetobacter baumannii). Susceptibility of at least 90% of the Acinetobacter isolates to tigecycline (with an MIC breakpoint of susceptibility < or =2 mg/L) was noted in 9/18 studies reporting data on MDR Acinetobacter and in 7/15 studies reporting specific data on carbapenem-resistant Acinetobacter. In an additional study reporting data for both resistance categories, adequate susceptibility of Acinetobacter spp. was observed by one (broth microdilution) of the methods employed. The effectiveness of tigecycline for MDR Acinetobacter infections was evaluated in eight identified clinical studies, reporting retrospective data regarding 42 severely ill patients, among whom 31 had respiratory tract infection (in 4 cases with secondary bacteraemia) and 4 had bacteraemia. Tigecycline therapy (in combination with other antibiotics in 28 patients) was effective in 32/42 cases. In three cases, resistance to tigecycline developed during treatment.
conclusionsTigecycline showed considerable, though not consistent, antimicrobial activity against MDR (including carbapenem-resistant) Acinetobacter spp. However, data to support its clinical use, particularly for ventilator-associated pneumonia or bacteraemia, caused by these pathogens, are still limited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.